SutroVax Secures $22,000,000 Series A Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=60dae837-6f77-433f-88e9-ba35a559b410 - Date
7/24/2015 - Company Name
SutroVax - Mailing Address
400 E Jamie Court South San Francisco, CA 94080 USA - Company Description
SutroVax is an independent vaccine platform and development company that was spun-out of Sutro Biopharma. The company will leverage Sutro’s Xpress CF and Xpress CF+ platforms for cell-free protein synthesis and site-specific conjugation to develop novel vaccines for an array of disease targets. - Website
http://www.sutrovax.com - Transaction Type
Venture Equity - Transaction Amount
$22,000,000 - Transaction Round
Series A - Proceeds Purposes
SutroVax will use the funds to advance multiple vaccines in its pipeline through pre-clinical proof of concept. - M&A Terms
- Venture Investor
Abingworth Management - Venture Investor
Longitude Capital Management - Venture Investor
Roche Venture Fund - Venture Investor
CTI Life Sciences Fund
